Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
PROVENTA Smart Database Transformation Framework (DATATRANS)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: Germany
Call: Open Disruptive Innovation Scheme (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2017-05-01
End date: 2017-08-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The execution of database migrations traditionally involves costs and risks that are difficult to evaluate previously. 40% of all migrations fail or exceed their budget and schedules. This prevents many organizations from implementing necessary changes to integrate better technologies, resulting in an extremely negative effect on their competitiveness in the long term. Major database vendors offer database migration tools to facilitate the adoption of their newest products, however, these tools focus only on database transformations to the vendor’s products and are only commercialized attached to the vendor package, which reinforces the vendor lock-in. Furthermore, migration tools focus on minimizing the impact of the migration process, without taking appropriate actions to avoid post-migration operational risks. At Proventa, we have gradually developed a series of custom utilities, based on commercial Open Source software, specifically for the purpose of database transformations. These tools have been progressively bundled into one single standalone package, called Datatrans. Datatrans constitutes a revolutionary standalone framework that drastically facilitates the transformation process for all the major database management systems. By releasing Datatrans as a commercial product, we will minimize migration project risks and encourage database transformations towards state-of-the art Open Source across all industries. This will result in a reduction of license costs, an improvement of general productivity and cost-efficiency. Additionally, this will also contribute to the general sustainability of Open Source database management software. For Proventa, on top of boosting our product revenues, it will also attract new customers and complement our current offer of consulting services. We estimate that Datatrans will allow us to double our revenue to almost €40 million by 2024, requiring us to hire at least 40 additional full time professionals.

Keywords: database transformation open source
Elucidating the propagation and function of H2A and H2B modifications across DNA replication (H2AH2B_Propagation)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Denmark
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2020-09-01
End date: 2022-12-05
Duration (months): 24.0
Total project cost (EUR): 207312.0
EU funding (EUR): 207312.0
Participants: 1
Project status: CLOSED

Chromatin and its accompanying histone marks are fundamental for correct, cell type-specific gene expression and thus important to ensure cellular identity of each cell. Importantly, this requires that the chromatin landscape is accurately propagated and maintained across DNA replication, a process which is still not well understood. While there have been insights into how histone H3 and H4 marks are transmitted to daughter cells, information on H2A and H2B marks are still missing. Using mouse embryonic stem cells, I will gain first insights into how modifications on H2A and H2B are maintained during DNA replication, and their impact on restoring the parental chromatin landscape on replicated DNA, with the following three specific objectives: (1) I will investigate the propagation principles and kinetics of H2A/H2B modifications during DNA replication using a combination of advanced mass spectrometry and genomic approaches with a focus on ubiquitinated H2A/H2B. (2) I will gain mechanistic insights into the importance of H2A/H2B ubiquitination on chromatin reestablishment with a degron-based depletion approach targeting H2A/H2B ubiquitin ligases. This will allow me to study if, where and how the H2Aub and H2Bub-dependent histone marks are reestablished and hence reveal important features of histone mark crosstalk during DNA replication. (3) I will determine whether H2A-H2B dimers are propagated symmetrically to the two daughter strands by employing a strand-specific sequencing approach, and test mutants wherein symmetric H3-H4 propagation is compromised. This proposal will provide pioneering insights into how histones H2A and H2B are propagated and unveil the epigenetic inheritance of their marks, and also bring seminal understanding of histone mark crosstalk during DNA replication and across cell division. This will open new research avenues in chromatin research and give me an unique opportunity to follow up on these mechanisms as future, independent researcher.

Keywords: dna replication,chromatin replication,epigenome maintenance,histone h2a and h2b,histone modifications,transcriptional regulation
THE CUSTOMISATION/PRE-OPERATIONALISATION OF WATER MANAGEMENT INNOVATIONS FROM SPACE FOR EUROPEAN CLIMATE RESILIENCE (PCP WISE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Food, Bioeconomy Natural Resources, Agriculture and Environment
Theme: Bio-Environment
Destination: Innovative governance, environmental observations and digital solutions in support of the Green Deal
Action type: Pre-Commercial Procurement
Countries involved: Spain,Netherlands,Finland,Slovakia,Germany,Greece,Denmark,Belgium,France
Call: Customisation/pre-operationalisation of prototypes end-user services in the area Climate Change Adaptation and Mitigation (HORIZON-CL6-2024-GOVERNANCE-01, 2024)
Start date: 2025-01-01
End date: 2027-12-31
Duration (months): 36.0
Total project cost (EUR): 18999999.25
EU funding (EUR): 18999999.25
Participants: 28
Project status: SIGNED

PCP-WISE aims to customize/pre-operationalize water management innovations from space for European climate resilience via pre-commercial procurement (PCP). The project, spanning phases from solution design to field validation, targets TRL 8. It addresses water-related crises (floods, fires, infrastructure impacts) using space and Earth Observation data. Objectives include common operational information products, interoperability mechanisms, and an active user network. With climate change impacting water availability and distribution, PCP-WISE seeks to enhance EO-based information for better regional water management, promoting resilience across EU borders. It focuses on local dynamics in water availability and aims to anticipate extreme climate conditions through an integrated water intelligence system. The project's significance lies in its potential to mitigate water-related crises, driven by a unified water taxonomy and Earth observation-based modeling. Through comprehensive research and development solutions, PCP-WISE aims to boost adaptation across the EU, targeting stakeholders in water management, environment, first responders, cities, and agriculture. The project's objectives are designed to adress business, technical, economic, and policy goals. Key results include capacity-building efforts, climate-related inputs, stakeholder engagement, and the dissemination of innovative solutions to advance water resilience both locally and globally.
Identifying mechanisms and novel treatments of bone pain – closing the gap to the clinic. (BonePainIII)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Doctoral Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Denmark,Sweden,Netherlands,Portugal,France,United Kingdom,Israel
Call: MSCA Doctoral Networks 2022 (HORIZON-MSCA-2022-DN-01, 2022)
Start date: 2024-01-01
End date: 2027-12-31
Duration (months): 48.0
Total project cost (EUR): 2833850.06
EU funding (EUR): 2578636.8
Participants: 13
Project status: SIGNED

Musculoskeletal pain from diseases such as arthritis and cancer in the bone affects the quality of life of millions and is a major societal burden. The current treatment options are opioids, non-steroid anti-inflammatory drugs and disease modifying drugs; however, these are often insufficient in providing an adequate pain relief. This is due to dose limiting side effects, the risk of misuse and addiction (opioids) and lack of efficacy. Thus, there is a strong unmet medical need. Drug development in pain has been hampered by a poor translation of preclinical data to the clinic and a lack of understanding of the underlying mechanisms. Therefore, in this project 4 academic beneficiaries, 3 industrial beneficiaries, 2 industrial partners and 4 academic partners join forces to create an outstanding and integrated training program for early stages researchers to increase the clinical translation of bone pain research and drug discovery and to provide novel mechanistic insight and potential therapeutic targets. We will develop fully humanized organ-on-a chip models of the painful bone disease microenvironment and we will use humanized mouse models, and tissue and liquid biopsies from patients to obtain clinically relevant data. Moreover, we will identify new disease mechanisms and potential treatment targets and explore the efficacy of clinical stage therapeutics in mouse models of the painful skeletal diseases osteoarthritis, rheumatoid arthritis, cancer in the bone and the rare bone disease, fibrous dysplasia. In an extensive training effort covering both specific research skills and transferable skills, the students will obtain an interdisciplinary, state-of-the-art and innovative training from the participants across sectors. The students will benefit from secondments with industrial partners and with some of the foremost pain researchers in Europe.

Keywords: bone pain musculoskeletal pain arthritis pain cancer pain pain in rare bone diseases
Cable-driven Arm Soft Re-configurable Exoskeleton for Muscle Impairment Rehabilitation (CASREx)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: United Kingdom
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-09-01
End date: 2027-08-31
Duration (months): 24.0
Total project cost (EUR): 276187.92
EU funding (EUR): 276187.92
Participants: 1
Project status: SIGNED

Upper limb muscles wrap around bones to aid Activities of Daily Living (ADLs) like eating, enhances leverage and joint stability. Conditions like stroke, along with an aging population, impair upper limb control, reducing Range of Motion (ROM) and force. Stroke incidence is rising, with costs and disability affecting millions. Rehabilitation Therapy (RT) is crucial for ADLs, it boosts self-esteem and reduces depression. Challenges include therapist shortages, which robotic exoskeletons offer solutions. Exoskeletons are wearable robots that enhance strength and mobility, mainly tested on stroke survivors. Benefits include reduced fatigue and improved range of motion. Cable-Driven Exoskeletons (CDEs) consist cables for actuation, and hence lightweight and improve comfort. CDEs can be divided into Cable Driven Rigid Exoskeletons (CDREs), with issues such as joint misalignment, affecting patient's mobility and comfort and Cable Driven Soft Exoskeletons (CDSEs), compliant in nature and offers superior comfort and flexibility with lightweight materials. However, existing CDSEs lacks 1) cable wrapping, mimicking muscle wrapping, and 2) dynamically movable cable attachment points, which improve force orientation, balanced joint torques, and manipulability. To tackle the challenges, I'm developing a lightweight, compact Cable-driven Arm Soft Re-configurable Exoskeleton (CASREx), featuring cable wrapping and dynamically moving cable attachment points via a Fibre Reinforced Soft Cable-driven Micro Actuator (FReSCMA). The research specific objectives are: SO1: FReSCMA design, characterization and testing (Work Package WP1)- Material selection, fabrication, and testing in CASREx. SO2: Modeling of FReSCMA and development of CASREx (WP2)- Kinematic modeling and CASREx design with an actuation and control box. SO3: CASREx control and pilot study(WP3)- Control for user assistance and cable tension reduction. This exoskeleton will be lightweight and adaptable to various ADLs.

Keywords: exoskeleton,soft robotics,cable driven robotics,kinematics and dynamics,rehabilitation,stroke
Development and validation of a framework using multiple sources of real-world data to assess the benefit-risk balance of advanced therapies in inflammatory bowel disease (FORECAST)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Prevention,  Diagnosis and T reatment of Human Diseases
Panel description: Medical technologies  and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions , pharmacology, preventative  medicine, epidemiology and public health , digital medicine
Countries involved: France
Call: ERC STARTING GRANTS (ERC-2024-STG, 2024)
Start date: 2024-12-01
End date: 2029-11-30
Duration (months): 60.0
Total project cost (EUR): 1473454.0
EU funding (EUR): 1473454.0
Participants: 2
Project status: SIGNED

Assessing the benefit-risk balance of treatment is crucial in medicine to select the most appropriate treatment for patients. This process faces major challenges, how to implement evidence in real time to guide treatment choice and how to summarize efficacy and safety outcomes to patients and clinicians, while incorporating patient preferences. Inflammatory bowel diseases (IBD) affect 3 million residents in Europe. New advanced therapies have been recently approved, but in the absence of head-to-head randomized controlled trials (RCT), data are lacking to position each drug in the therapeutic management. Multiple types of real-world data (RWD) sources are available to assess the effect of treatment, but each type has its proper strengths and limitations. Linking multiple RWD sources can overcome limitations and leverage the strengths of each data source. We recently emulated clinical trials supporting the use of RWD to assess treatment effectiveness and safety in IBD. Based on the linkage of nationwide healthcare databases, electronic health records, and a prospective cohort of IBD patients, the aims of the current proposal are (i) to validate algorithms identifying IBD characteristics and outcomes in nationwide healthcare databases, (ii) to emulate head-to-head clinical trials comparing advanced therapies in IBD, (iii) to incorporate trials findings and patient preferences in a clinical decision support system for IBD patients and clinicians, whose impact will be assessed by a pragmatic RCT nested in nationwide healthcare databases. This challenging project will involve multi-disciplinary aspects, from qualitative approach to artificial intelligence, to clarify the position of each treatment in IBD and disseminate findings to patients and clinicians. Besides scientific importance, it will have societal impact by setting the stage for a novel post-marketing drug surveillance framework applicable not only to future IBD treatments but also to other chronic diseases.

Keywords: pharmacoepidemiology gastroenterology inflammatory bowel diseases administrative health databases
Sepsis Diagnosis via Integrated Breath Sensing System with Change-Point Detection for Real-Time Point-of-Care (SepsISensoR)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Cyprus
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-10-03
End date: 2025-11-02
Duration (months): 37.0
Total project cost (EUR): 148488.0
EU funding (EUR): 148488.0
Participants: 1
Project status: SIGNED

Every 2.8 seconds someone dies from sepsis: 11 million people annually, out of which children under 5 years old. Septic shock is the potentially fatal body’s dysregulated response to pathogens that spread through blood circulation, including viruses like SARS-CoV-2. Half of sepsis cases happen in ICUs with 42% morality, with costs of €30 000 per case and €20 billion per year. Current diagnosis protocols rely on observation of the clinical symptoms to initiate regular monitoring of patients’ vital signs. Blood analyses and other tests identify the source of infection within 2-5 days, during which broad-spectrum antibiotics are administered, contributing to antibiotic resistance. Every hour of delay increases the mortality rate by 5-10%. Hence, early diagnosis of the infection source is a major step towards treatment. Pre-clinical and commercial point-of-care devices reduce the analysis time to few hours but still rely on the manifestation of clinical symptoms and invasive blood-based assays. SepsISensoR will advance the sepsis diagnosis protocol by non-invasive real-time monitoring of ICU patients’ breath to detect pre-symptomatic signs of sepsis based on transient changes of gas biomarkers in early sepsis stages. This will be achieved by: (a) integrating commercial gas sensors with fabricated preconcentrators on a single chip for high sensitivity, efficient and scalable multiple gas sensing; (b) using on-line change-point detection (CPD) on the breath signal to identify temporal variations of single- and multi-gas concentration; (c) validating the system with gases released from in vitro and in vivo models of sepsis. SepsISensoR will go beyond the state-of-the-art by reducing diagnosis time, and in turn reducing time in ICUs, cost, and sepsis fatalities. This aligns with Pillar I Excellent Science MSCA fellowship under the European Research Council and Key Strategic Orientation A with Cluster 1 of the Work Programme on technologies for healthy society.

Keywords: electronic gas sensing systems,biomedical breath diagnostics
A thermoelectric generator for low-grade heat to electricity/hydrogen conversion (H2E) (H2E)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: Belgium
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-09-01
End date: 2024-08-31
Duration (months): 24.0
Total project cost (EUR): 191760.0
EU funding (EUR): 191760.0
Participants: 1
Project status: CLOSED

Heat-to-power conversion can be achieved by thermoelectric generators (TEGs), devices that exploit the Seebeck effect to build up an electric potential across a stack of semiconductors subjected to a temperature difference. This physical effect has long been known, but widespread application has remained limited because of the low efficiency (less than 5%) and high cost of available semiconductors, often containing rare metals and featuring high toxicity and poor thermal stability. Compared to alternative technologies for valorisation of low-grade heat, e.g., the Organic Rankine Cycle, TEG technology has substantial advantages, including lower weight and absence of moving parts. This leads to high reliability and low-maintenance, crucial attributes for the chemical process industry. Using less expensive semiconductor materials and increasing efficiency are the main challenges to broaden the application field of TEGs. H2E proposes a new approach to enable improved TEGs using a thermo-electrochemical-hydrogen production device (TEC-H) based on recently discovered, robust, low cost, non-toxic porous semiconductor materials. These new semiconductors are implemented in an original design, mounting them in stacks to produce a TEC-H device that is modular and exhibits good scalability. The resulting disruptive increase in efficiency will enable power generation with a decreased cost per unit power. H2E will valorise low-grade waste heat in the temperature range below 100 °C, a range currently not exploited in industry. Besides industrial waste heat, also low-grade geothermal heat represents huge potential. H2E aims to innovate the production of two end products: renewable electricity and green hydrogen - by water splitting. H2E will contribute to a more energy-efficient and low-carbon future, in line with Europe’s long-term strategy to become climate-neutral by 2050 as set by the European Commission in The European Green Deal.

Keywords: thermoelectric generator,thermocouples,energy conversion,seebek effect
Perovskite solar cells with enhanced stability and applicability (VALHALLA)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Energy
Destination: Sustainable, secure and competitive energy supply
Action type: Research and Innovation actions
Countries involved: Spain,Lithuania,Netherlands,Italy,Belgium,Switzerland,United Kingdom,Finland,France
Call: Stable high-performance Perovskite Photovoltaics (HORIZON-CL5-2021-D3-03, 2021)
Start date: 2023-01-01
End date: 2025-12-31
Duration (months): 36.0
Total project cost (EUR): 3877396.5
EU funding (EUR): 3877396.5
Participants: 14
Project status: SIGNED

VALHALLA will develop perovskite solar cells and modules with power conversion efficiencies above 26% (23% for modules) and an extrapolated lifetime > 25 years, guided by eco-design principles that decrease the environmental impact of perovskite photovoltaics: scalable production processes, no harmful solvents, optimised use of materials, circularity and recyclability. Only lead-based perovskites have demonstrated efficiencies and stabilities that enable to reach the targeted performance levels. Therefore, in VALHALLA we focus primarily on lead based perovskites. We will develop innovative encapsulation methods containing lead-chelating materials that detain all lead even in broken modules. Circularity will be demonstrated, including a full end-of-life recovery of lead. We will focus on vacuum and hybrid processing that eliminates the use of toxic and harmful solvents during production. To increase the range of application of this sustainable technology, VALHALLA will develop rigid, flexible and semi-transparent perovskites with three bandgap ranges together with their optimized charge transport materials. Understanding the degradation mechanisms of both cells and modules in outdoor operating conditions and developing meaningful accelerated indoor stability tests for perovskite will be a key target of VALHALLA. The approach to stability will be from a global angle, from the theoretical understanding of the role of perovskite defects, composition, and architecture on the intrinsic stability to the development of module encapsulation and interconnection design that will enable long operational lifetime. An energy yield assessment will be performed based on outdoor stressed modules in three different European locations.

Keywords: perovskite,photovoltaics,stability,high efficiency,flexible,semi transparent